The clinical effectiveness of mepolizumab treatment in severe eosinophilic asthma; outcomes from four years cohort evaluation

References

• Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, et al. Global initiative for asthma strategy 2021: executive summary and rationale for key changes. J Allergy Clin Immunol Pract. 2022;10(1S):S1–S18. doi:10.1016/j.jaip.2021.10.001.
   PubMedGoogle Scholar
• Holguin F, Cardet JC, Chung KF, Diver S, Ferreira DS, Fitzpatrick A, Gaga M, Kellermeyer L, Khurana S, Knight S, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. doi:10.1183/13993003.00588-2019.
   PubMed Web of Science ®Google Scholar
• Pelaia C, Paoletti G, Puggioni F, Racca F, Pelaia G, Canonica GW, Heffler E. Interleukin-5 in the pathophysiology of severe asthma. Front Physiol. 2019;10:1514. doi:10.3389/fphys.2019.01514.
   PubMed Web of Science ®Google Scholar
• Roufosse F. Targeting the interleukin-5 pathway for treatment of eosinophilic conditions other than asthma. Front Med (Lausanne). 2018;5:49. doi:10.3389/fmed.2018.00049.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291.
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X.
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi:10.1016/S2213-2600(17)30125-X.
   PubMed Web of Science ®Google Scholar
• Moore WC, Kornmann O, Humbert M, Poirier C, Bel EH, Kaneko N, Smith SG, Martin N, Gilson MJ, Price RG, et al. Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study). Eur Respir J. 2022;59(1):2100396. doi:10.1183/13993003.00396-2021.
   PubMed Web of Science ®Google Scholar
• Khurana S, Brusselle GG, Bel EH, FitzGerald JM, Masoli M, Korn S, Kato M, Albers FC, Bradford ES, Gilson MJ, et al. Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study. Clin Ther. 2019;41(10):2041–2056. doi:10.1016/j.clinthera.2019.07.007.
   PubMed Web of Science ®Google Scholar
• Khatri S, Moore W, Gibson PG, Leigh R, Bourdin A, Maspero J, Barros M, Buhl R, Howarth P, Albers FC, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019;143(5):1742–1751.e7. doi:10.1016/j.jaci.2018.09.033.
   PubMed Web of Science ®Google Scholar
• Mepolizumab for treating severe eosinophilic asthma Technology appraisal guidance Published: 3 February 2021. www.nice.org.uk/guidance/ta671. [accessed 07 August 2022].
   Google Scholar
• Albers FC, Licskai C, Chanez P, Bratton DJ, Bradford ES, Yancey SW, Kwon N, Quirce S. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. Respir Med. 2019;159:105806. doi:10.1016/j.rmed.2019.105806.
   PubMed Web of Science ®Google Scholar
• Elsey L, Pantin T, Holmes L-J, Tavernier G, Fowler SJ. Outcomes over the first two years of treatment with mepoli­zumab in severe asthma. Eur Respir J. 2021;58(6):2101313. doi:10.1183/13993003.01313-2021.
   PubMed Web of Science ®Google Scholar
• van Toor JJ, van der Mark SC, Kappen JH, In ‘t Veen JCCM, Braunstahl GJ. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety. J Asthma. 2021;58(5):651–658. doi:10.1080/02770903.2020.1723623.
   PubMed Web of Science ®Google Scholar
• Nair P. Predictors of response to anti-IL-5 biologics. Respirology. 2020;25(11):1123–1125. doi:10.1111/resp.13926.
   PubMedGoogle Scholar
• McGregor MC, Krings JG, Nair P, Castro M. Role of Biologics in Asthma. Am J Respir Crit Care Med. 2019;199(4):433–445. doi:10.1164/rccm.201810-1944CI.
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, Green L, Fernandes M, Jackson DJ, Kent B, Roxas C. P134 Real world experience of mepolizumab in steroid-dependent severe eosinophilic asthma: one year outcomes. Thorax. 2018;73:174–5.
   PubMed Web of Science ®Google Scholar
• Mansur AH, Gonem S, Brown T, Burhan H, Chaudhuri R, Dodd JW, Pantin T, Gore R, Jackson D, Menzies-Gow A, et al. Biologic therapy practices in severe asthma; outcomes from the UK Severe Asthma Registry and survey of specialist opinion. Clin Exp Allergy. 2022. doi:10.1111/cea.14222.
   Web of Science ®Google Scholar
• Harrison T, Canonica GW, Chupp G, Lee J, Schleich F, Welte T, Valero A, Gemzoe K, Maxwell A, Joksaite S, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020;56(4):2000151. doi:10.1183/13993003.00151-2020.
   PubMed Web of Science ®Google Scholar
• Upham JW, Le Lievre C, Jackson DJ, Masoli M, Wechsler ME, Price DB, Panel D. Defining a severe asthma super-responder: findings from a Delphi process. J Allergy Clin Immunol Pract. 2021;9(11):3997–4004. doi:10.1016/j.jaip.2021.06.041.
   PubMed Web of Science ®Google Scholar
• Harvey ES, Langton D, Katelaris C, Stevens S, Farah CS, Gillman A, Harrington J, Hew M, Kritikos V, Radhakrishna N, et al. Mepolizumab effectiveness and identification of super-responders in severe asthma. Eur Respir J. 2020;55(5):1902420. doi:10.1183/13993003.02420-2019.
   PubMed Web of Science ®Google Scholar
• McDowell PJ, Diver S, Yang F, Borg C, Busby J, Brown V, Shrimanker R, Cox C, Brightling CE, Chaudhuri R, et al. The inflammatory profile of exacerbations in patients with severe refractory eosinophilic asthma receiving mepolizumab (the MEX study): a prospective observational study. Lancet Respir Med. 2021;9(10):1174–1184. doi:10.1016/S2213-2600(21)00004-7.
   PubMed Web of Science ®Google Scholar
• d’Ancona G, Kavanagh J, Roxas C, Green L, Fernandes M, Thomson L, Dhariwal J, Nanzer AM, Jackson DJ, Kent BD. Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma. Eur Respir J. 2020;55(5):1902259. doi:10.1183/13993003.02259-2019.
   PubMed Web of Science ®Google Scholar
• Korn S, Howarth P, Smith SG, Price RG, Yancey SW, Prazma CM, Bel EH. Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma. Respir Res. 2022;23(1):45. doi:10.1186/s12931-022-01959-1.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Gurnell M, Heaney LG, Corren J, Bel EH, Maspero J, Harrison T, Jackson DJ, Price D, Lugogo N, et al. Adrenal function recovery after durable OCS-sparing with benralizumab in the PONENTE study. Eur Respir J. 2022;60(6):2103226. doi:10.1183/13993003.03226-2021.
   PubMed Web of Science ®Google Scholar
• Israel E, Canonica GW, Brusselle G, Yang S, Howarth PH, Martin AL, Koufopoulou M, Smith SG, Alfonso-Cristancho R. Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review. J Asthma. 2021;59(11):2201–2217. doi:10.1080/02770903.2021.2008431.
   PubMed Web of Science ®Google Scholar
• Schleich F, Chaudhuri R, Canonica GW, Munoz Gall X, Funke F, Pek B, Pollard S, Maxwell A, Joksaite S, Price RG, et al. Mepolizumab improves lung function under real-world settings in REALITI-A study. Eur Respir J. 2020;56(suppl 64):2260. doi:10.1183/13993003.congress-2020.2260.
   Google Scholar
• Ramonell RP, Lee FE, Levy JM, Kuruvilla M. Exhaled nitric oxide measurements are not influenced by anti-eosinophil therapy in patients with asthma, A retrospective analysis. Ann Allergy Asthma Immunol. 2021;126(1):102–104. doi:10.1016/j.anai.2020.09.005.
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Mansur AH, Brightling CE. Clinical utility of fractional exhaled nitric oxide in severe asthma management. Eur Respir J. 2020;55(3):1901633. doi:10.1183/13993003.01633-2019.
   PubMed Web of Science ®Google Scholar
• Heaney LG, Busby J, Bradding P, Chaudhuri R, Mansur AH, Niven R, Pavord ID, Lindsay JT, Costello RW. Remotely monitored therapy and nitric oxide suppression identifies nonadherence in severe asthma. Am J Respir Crit Care Med. 2019;199(4):454–464. doi:10.1164/rccm.201806-1182OC.
   PubMed Web of Science ®Google Scholar
• Ray A, Raundhal M, Oriss TB, Ray P, Wenzel SE. Current concepts of severe asthma. J Clin Invest. 2016;126(7):2394–2403. doi:10.1172/JCI84144.
   PubMed Web of Science ®Google Scholar